Bacillus Calmette-Guerin

Is monthly maintenance an option for transitional cell carcinoma of the bladder?

Robert C. Flanigan, Dino A. DeLaurentis, W Waters, Karen Kunz

Research output: Contribution to journalArticle

Abstract

Purpose: Recently, a Southwest Oncology Group study (SWOG 8507) demonstrated increased efficacy for a bacillus Calmette-Guerin (BCG) maintenance (mtce) program (3 weekly treatments at 3 months, 6 months, and every 6 months thereafter for 3 years) following 6 weekly instillations with BCG as compared to no mtce ('6+3' protocol). The remarkable results from the mtce arm were unfortunately accompanied by grade 3 or 4 toxicity in 26%. In fact; only 16% of the patients in the maintenance arm received BCG at each of the 7 prescribed courses. Herein, we report on a series of 37 patients with high risk (rapidly recurring grade 2 or 3) Ta, T1 transitional cell carcinoma (TCC) or carcinoma in situ (TIS) of the bladder who received 6 weekly BCG treatments followed by monthly mtce for one year. Patients and Methods: This was a prospective, non-randomized trial of 37 patients with high risk superficial transitional cell carcinoma (TCC) who received one or two 6-week induction courses of intravesical Tice BCG, followed by monthly mtce for 12 months. Entry criteria were identical to those of SWOG 8507. The mean follow-up interval was 40.7 months. Results: Twenty eight of thirty-seven patients (75.7%) remained free of disease recurrence at a median of 40.7 (range 13-101) months. Only one patient progressed to muscle invasive disease. Only 1 of 37 (2.7%) patient experienced grade 3/4 toxicity. Conclusion: In this single institution, monthly maintenance protocol, freedom from recurrence was significant with dramatically less grade 3 or 4 toxicity than reported in SWOG 8507. Copyright (C) 2001 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)16-19
Number of pages4
JournalUrologic Oncology
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Transitional Cell Carcinoma
Mycobacterium bovis
Urinary Bladder
Maintenance
Recurrence
Carcinoma in Situ
Muscles
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Cite this

Bacillus Calmette-Guerin : Is monthly maintenance an option for transitional cell carcinoma of the bladder? / Flanigan, Robert C.; DeLaurentis, Dino A.; Waters, W; Kunz, Karen.

In: Urologic Oncology, Vol. 6, No. 1, 01.01.2001, p. 16-19.

Research output: Contribution to journalArticle

Flanigan, Robert C. ; DeLaurentis, Dino A. ; Waters, W ; Kunz, Karen. / Bacillus Calmette-Guerin : Is monthly maintenance an option for transitional cell carcinoma of the bladder?. In: Urologic Oncology. 2001 ; Vol. 6, No. 1. pp. 16-19.
@article{78173be610e34c9bb0b7fed6ce97544e,
title = "Bacillus Calmette-Guerin: Is monthly maintenance an option for transitional cell carcinoma of the bladder?",
abstract = "Purpose: Recently, a Southwest Oncology Group study (SWOG 8507) demonstrated increased efficacy for a bacillus Calmette-Guerin (BCG) maintenance (mtce) program (3 weekly treatments at 3 months, 6 months, and every 6 months thereafter for 3 years) following 6 weekly instillations with BCG as compared to no mtce ('6+3' protocol). The remarkable results from the mtce arm were unfortunately accompanied by grade 3 or 4 toxicity in 26{\%}. In fact; only 16{\%} of the patients in the maintenance arm received BCG at each of the 7 prescribed courses. Herein, we report on a series of 37 patients with high risk (rapidly recurring grade 2 or 3) Ta, T1 transitional cell carcinoma (TCC) or carcinoma in situ (TIS) of the bladder who received 6 weekly BCG treatments followed by monthly mtce for one year. Patients and Methods: This was a prospective, non-randomized trial of 37 patients with high risk superficial transitional cell carcinoma (TCC) who received one or two 6-week induction courses of intravesical Tice BCG, followed by monthly mtce for 12 months. Entry criteria were identical to those of SWOG 8507. The mean follow-up interval was 40.7 months. Results: Twenty eight of thirty-seven patients (75.7{\%}) remained free of disease recurrence at a median of 40.7 (range 13-101) months. Only one patient progressed to muscle invasive disease. Only 1 of 37 (2.7{\%}) patient experienced grade 3/4 toxicity. Conclusion: In this single institution, monthly maintenance protocol, freedom from recurrence was significant with dramatically less grade 3 or 4 toxicity than reported in SWOG 8507. Copyright (C) 2001 Elsevier Science Inc.",
author = "Flanigan, {Robert C.} and DeLaurentis, {Dino A.} and W Waters and Karen Kunz",
year = "2001",
month = "1",
day = "1",
doi = "10.1016/S1078-1439(00)00099-5",
language = "English (US)",
volume = "6",
pages = "16--19",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Bacillus Calmette-Guerin

T2 - Is monthly maintenance an option for transitional cell carcinoma of the bladder?

AU - Flanigan, Robert C.

AU - DeLaurentis, Dino A.

AU - Waters, W

AU - Kunz, Karen

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Purpose: Recently, a Southwest Oncology Group study (SWOG 8507) demonstrated increased efficacy for a bacillus Calmette-Guerin (BCG) maintenance (mtce) program (3 weekly treatments at 3 months, 6 months, and every 6 months thereafter for 3 years) following 6 weekly instillations with BCG as compared to no mtce ('6+3' protocol). The remarkable results from the mtce arm were unfortunately accompanied by grade 3 or 4 toxicity in 26%. In fact; only 16% of the patients in the maintenance arm received BCG at each of the 7 prescribed courses. Herein, we report on a series of 37 patients with high risk (rapidly recurring grade 2 or 3) Ta, T1 transitional cell carcinoma (TCC) or carcinoma in situ (TIS) of the bladder who received 6 weekly BCG treatments followed by monthly mtce for one year. Patients and Methods: This was a prospective, non-randomized trial of 37 patients with high risk superficial transitional cell carcinoma (TCC) who received one or two 6-week induction courses of intravesical Tice BCG, followed by monthly mtce for 12 months. Entry criteria were identical to those of SWOG 8507. The mean follow-up interval was 40.7 months. Results: Twenty eight of thirty-seven patients (75.7%) remained free of disease recurrence at a median of 40.7 (range 13-101) months. Only one patient progressed to muscle invasive disease. Only 1 of 37 (2.7%) patient experienced grade 3/4 toxicity. Conclusion: In this single institution, monthly maintenance protocol, freedom from recurrence was significant with dramatically less grade 3 or 4 toxicity than reported in SWOG 8507. Copyright (C) 2001 Elsevier Science Inc.

AB - Purpose: Recently, a Southwest Oncology Group study (SWOG 8507) demonstrated increased efficacy for a bacillus Calmette-Guerin (BCG) maintenance (mtce) program (3 weekly treatments at 3 months, 6 months, and every 6 months thereafter for 3 years) following 6 weekly instillations with BCG as compared to no mtce ('6+3' protocol). The remarkable results from the mtce arm were unfortunately accompanied by grade 3 or 4 toxicity in 26%. In fact; only 16% of the patients in the maintenance arm received BCG at each of the 7 prescribed courses. Herein, we report on a series of 37 patients with high risk (rapidly recurring grade 2 or 3) Ta, T1 transitional cell carcinoma (TCC) or carcinoma in situ (TIS) of the bladder who received 6 weekly BCG treatments followed by monthly mtce for one year. Patients and Methods: This was a prospective, non-randomized trial of 37 patients with high risk superficial transitional cell carcinoma (TCC) who received one or two 6-week induction courses of intravesical Tice BCG, followed by monthly mtce for 12 months. Entry criteria were identical to those of SWOG 8507. The mean follow-up interval was 40.7 months. Results: Twenty eight of thirty-seven patients (75.7%) remained free of disease recurrence at a median of 40.7 (range 13-101) months. Only one patient progressed to muscle invasive disease. Only 1 of 37 (2.7%) patient experienced grade 3/4 toxicity. Conclusion: In this single institution, monthly maintenance protocol, freedom from recurrence was significant with dramatically less grade 3 or 4 toxicity than reported in SWOG 8507. Copyright (C) 2001 Elsevier Science Inc.

UR - http://www.scopus.com/inward/record.url?scp=0035216287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035216287&partnerID=8YFLogxK

U2 - 10.1016/S1078-1439(00)00099-5

DO - 10.1016/S1078-1439(00)00099-5

M3 - Article

VL - 6

SP - 16

EP - 19

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 1

ER -